SY65 - Metabotyping for Precision Obesity Treatment: Bridging Lifestyle, Surgical, & Pharmacologic Interventions

Symposium Chair(s)

• 

  Bradley Javorsky, MD

  Associate Professor of Medicine
  Medical College of Wisconsin
  Milwaukee, WI, United States

  Disclosure(s): Chiesi Farmaceutici: Clinical Trial Investigator ()
• 

  Milay LUIS LAM, MD

  Clinical Associate Professor of Medicine
  Meritus Medical Center
  Frederick, MD, United States

  Disclosure(s): No financial relationships to disclose

Recent advances in obesity pharmacotherapy are transforming metabolic care through increasingly potent and diverse mechanisms of action. This session will explore next-generation injectable incretin-based agents, including dual and triple receptor agonists; oral and nonpeptide anti-obesity medications designed to improve accessibility, adherence, and long-term weight maintenance; and emerging pathways beyond gut hormones that may redefine how obesity and metabolic diseases are treated. Speakers will integrate preclinical and clinical insights to highlight innovation in drug design, efficacy, and durability-offering a forward-looking view of the evolving therapeutic landscape for obesity.

Presentations:

• 9:00 AM - 9:30 AM CT

  Definition and Diagnostic Criteria of Obesity - Considering the Heterogeneity of Obesity
  

  Symposium Speaker: Marc-Andre Cornier, MD – Medical University of South Carolina
• 9:30 AM - 10:00 AM CT

  Precision Obesity Care: From Behavioral Clusters to Metabotypes to Precision Pharmacotherapy
  

  Symposium Speaker: Maria Daniela Hurtado Andrade
• 10:00 AM - 10:30 AM CT

  Metabolic Predictors of Surgical Response: Preventing Insufficient Weight Loss and Regain
  

  Symposium Speaker: Mariana P. Monteiro, MD, PhD (she/her/hers) – ICBAS- University of Porto